The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Updated 06/21/2024

Status Approved for marketing

Clinical Trial Summary

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00438789
Study type	Expanded Access
Source	Alexion Pharmaceuticals
Contact
Status	Approved for marketing
Phase	Phase 3

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00997386` - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States	Phase 2
	Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
	Completed	`NCT00122330` - Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients	Phase 3
	Completed	`NCT00867932` - Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 4
	Completed	`NCT00721864` - The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)	N/A
	Completed	`NCT00152139` - Stem Cell Transplantation for Patients With Hematologic Malignancies	Phase 3
	Active, not recruiting	`NCT01642979` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Phase 2
	Active, not recruiting	`NCT01760096` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Phase 2
	Completed	`NCT00618969` - Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors	Phase 2
	Completed	`NCT00122304` - Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab	Phase 3
	Completed	`NCT00098280` - Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria	Phase 3
	Recruiting	`NCT01224483` - Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients	N/A
	Active, not recruiting	`NCT00315419` - Identifying Characteristics of Bone Marrow Failure Syndromes	N/A